We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
-2.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$415M
AUM Growth
-$201M
(-33%)
Cap. Flow
+$2.08M
Cap. Flow % of AUM
Cap. Flow %
0.5%
Top 10 Holdings %
Top 10 Hldgs %
36.85%
Holding
112
New
24
Increased
13
Reduced
25
Closed
42
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.3
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$17.7M |
| 2 |
Merck
MRK
|
+$13.8M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$9.02M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$8.34M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$7.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$10.2M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$9.9M |
| 3 |
CYNO
Cynosure, Inc. Class A
CYNO
|
+$7.64M |
| 4 |
Pacific Biosciences
PACB
|
+$6.72M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
+$6.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.7% |
| 2 | Miscellaneous | 22.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $35.5M | 8.55% |
600,000
-150,000
| -20% | -$9.26M |
2016 Q1
3 quarters
|
|
|
SHPG
2
DELISTED
Shire pic
SHPG
| $17M | 4.1% |
+100,000
| New | +$17.7M |
2016 Q4
0 quarters
|
|
3
Abbott
ABT
$191B
| $15.4M | 3.7% |
400,000
+100,000
| +33% | +$3.97M |
2016 Q3
1 quarter
|
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $14.1M | 3.39% |
115,000
-5,000
| -4% | -$612K |
2016 Q1
3 quarters
|
|
5
Zimmer Biomet
ZBH
$20.6B
| $13.4M | 3.23% |
133,900
+5,150
| +4% | +$552K |
2016 Q3
1 quarter
|
|
|
6
Merck
MRK
$366B
| $13.2M | 3.19% |
+235,800
| New | +$13.8M |
2016 Q4
0 quarters
|
|
|
CELG
7
DELISTED
Celgene Corp
CELG
| $12.7M | 3.06% |
110,000
+10,000
| +10% | +$1.11M |
2016 Q1
3 quarters
|
|
8
DBV Technologies S.A. American Depositary Shares
DBVT
$688M
| $11.4M | 2.75% |
32,500
+7,500
| +30% | +$2.69M |
2016 Q3
1 quarter
|
|
9
DELISTED
Sage Therapeutics
SAGE
| $10.2M | 2.46% |
200,000
+25,000
| +14% | +$1.18M |
2016 Q3
1 quarter
|
|
|
NUVA
10
DELISTED
NuVasive, Inc.
NUVA
| $10.1M | 2.43% |
150,000
-60,000
| -29% | -$3.87M |
2014 Q3
9 quarters
|
|
11
CALL
Acadia Pharmaceuticals
ACAD
$3.4B
| $10.1M | 2.43% |
+350,000
| New | +$9.26M |
2016 Q4
0 quarters
|
|
|
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.8M | 2.35% |
220,000
-280,000
| -56% | -$9.9M |
2016 Q1
3 quarters
|
|
13
Boston Scientific
BSX
$63.8B
| $9.7M | 2.34% |
450,000
+50,000
| +13% | +$1.09M |
2016 Q1
3 quarters
|
|
14
CALL
Bristol-Myers Squibb
BMY
$128B
| $8.77M | 2.11% |
150,000
-50,000
| -25% | -$2.73M |
2016 Q3
1 quarter
|
|
|
AVXS
15
DELISTED
AveXis, Inc. Common Stock
AVXS
| $8.35M | 2.01% |
175,000
+148,464
| +559% | +$7.93M |
2016 Q3
1 quarter
|
|
|
SPNC
16
DELISTED
Spectranetics Corp
SPNC
| $8.21M | 1.98% |
335,000
-100,000
| -23% | -$2.35M |
2015 Q3
5 quarters
|
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.92M | 1.91% |
+150,000
| New | +$9.02M |
2016 Q4
0 quarters
|
|
|
18
CALL
Abbott
ABT
$191B
| $7.68M | 1.85% |
+200,000
| New | +$7.93M |
2016 Q4
0 quarters
|
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $7.61M | 1.83% |
+70,000
| New | +$8.34M |
2016 Q4
0 quarters
|
|
|
NDRM
20
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $7.33M | 1.76% |
330,000
+199,000
| +152% | +$3.72M |
2016 Q3
1 quarter
|
|
21
BioCryst Pharmaceuticals
BCRX
$1.97B
| $7.28M | 1.75% |
1,150,000
-650,000
| -36% | -$3.38M |
2016 Q2
2 quarters
|
|
22
Glaukos
GKOS
$13.8B
| $6.86M | 1.65% |
+200,000
| New | +$6.85M |
2016 Q4
0 quarters
|
|
23
Iovance Biotherapeutics
IOVA
$4B
| $6.78M | 1.63% |
975,000
+150,000
| +18% | +$1.03M |
2016 Q1
3 quarters
|
|
|
MNK
24
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $6.73M | 1.62% |
+135,000
| New | +$7.95M |
2016 Q4
0 quarters
|
|
|
AERI
25
DELISTED
Aerie Pharmaceuticals
AERI
| $6.62M | 1.59% |
175,000
+50,000
| +40% | +$1.89M |
2016 Q3
1 quarter
|
|
Similar funds
AFS
E
Ghost Tree Capital's Q4 2016 Portfolio in Review
As of Q4 2016, Ghost Tree Capital held 112 positions worth $415M, down 33% from $617M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Ghost Tree Capital's Q4 2016 filing shows 24 new, 13 increased, 25 reduced and 42 closed positions. Its largest new stake was Shire pic: 100,000 shares worth $17M. The largest sale was Edwards Lifesciences, an estimated $10.2M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 55% a quarter earlier, followed by Miscellaneous.
- Ghost Tree Capital's largest Q4 2016 buy was Shire pic: 100,000 shares worth $17M.
- Ghost Tree Capital added most to AveXis, Inc. Common Stock in Q4 2016, an estimated $7.93M increase.
- Ghost Tree Capital's biggest Q4 2016 reduction was Clovis Oncology, Inc., cutting an estimated $9.9M.
- Ghost Tree Capital fully exited Edwards Lifesciences in Q4 2016, selling an estimated $10.2M.
- Ghost Tree Capital's ten largest holdings make up 37% of its $415M portfolio in Q4 2016.
- Ghost Tree Capital opened 24 new positions and closed 42 in Q4 2016.
- Ghost Tree Capital's portfolio value fell 33% quarter-over-quarter to $415M.
Based on Ghost Tree Capital's 13F filing for Q4 2016, filed 14 Feb 2017.